Contact

What are you looking for?

Biosafety & Safety by Design: Identifying Adventitious Agents in Cell & Gene Therapy Production

November 13, 2020
Download Now

In this document we look at cell and gene therapies (CGTs), an important growth sector for the biopharmaceutical industry. The US Food and Drug Administration (FDA) has now approved several CGTs for use in humans. CGT has, however, highlighted deficiencies in traditional safety models, reinforcing the need for a holistic approach to biosafety.

Identifying Adventitious Agents in Cell Gene Therapy Production

Please complete the form to download your copy.

    Related White Papers

    News & Insights

    • SGS Life Science Services Global

    1 Place des Alpes,

    P.O. Box 2152 1211,

    Geneva Switzerland